<DOC>
	<DOCNO>NCT00316901</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , positron emission tomography compute tomography scan ( do cellular adoptive immunotherapy ) , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This phase II trial study well positron emission tomography compute tomography scan predicts response patient metastatic melanoma kidney cancer undergo cellular adoptive immunotherapy Surgery Branch clinical trial .</brief_summary>
	<brief_title>Positron Emission Tomography CT Scan Predicting Response Patients With Metastatic Melanoma Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy Surgery Branch Clinical Trial</brief_title>
	<detailed_description>OBJECTIVES : Primary - Measure change metabolic activity visceral site acute treatment phase adoptive cell transfer ( ACT ) use positron emission tomography ( PET ) /CT fusion image patient metastatic melanoma renal cell cancer . - Measure change metabolic activity metastatic site acute treatment phase ACT use PET/CT fusion imaging . - Compare change metabolic activity visceral metastatic site patient treat intravenous vs intra-arterial tumor-infiltrating lymphocyte infusion . Secondary - Correlate response individual metastases metabolic alteration . OUTLINE : This pilot study . Patients stratify accord treatment ( intravenous [ IV ] tumor-infiltrating lymphocyte [ TIL ] nonmyeloablative preparative regimen v intra-arterial [ IA ] TIL nonmyeloablative preparative regimen vs IV TIL myeloablative preparative regimen chemotherapy total-body irradiation ) . Patients undergo positron emission tomography fludeoxyglucose F 18 ( FDG-PET ) /CT fusion image baseline ( start TIL infusion ) , day 1-4 TIL infusion , day 5-8 TIL infusion . PROJECTED ACCRUAL : A total 70 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Melanoma Renal cell cancer Metastatic disease Measurable disease CT scan MRI Enrolled Surgery Branch protocol utilize 1 follow variation adoptive cell transfer tumorinfiltrating lymphocyte ( TIL ) : Intravenous ( IV ) TIL nonmyeloablative preparative regimen ( e.g. , NCI99C0158 ) Intraarterial ( IA ) TIL nonmyeloablative preparative regimen ( e.g. , NCI99C0158 ) IV TIL myeloablative preparative regimen chemotherapy totalbody irradiation ( e.g. , NCI04C0288 ) PATIENT CHARACTERISTICS : ECOG performance status 02 No history treatment diabetes mellitus No hypersensitivity allergy fludeoxyglucose F 18 Weight â‰¤ 350 lb ( 136 kg ) Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : See Disease Characteristics No treatment IV IA TIL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>